MCID: DBT005
MIFTS: 54

Diabetes Insipidus

Categories: Endocrine diseases, Nephrological diseases, Rare diseases, Neuronal diseases

Aliases & Classifications for Diabetes Insipidus

MalaCards integrated aliases for Diabetes Insipidus:

Name: Diabetes Insipidus 12 76 29 6 43 44 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:9409
ICD10 33 E23.2
ICD9CM 35 253.5
MeSH 44 D003919
NCIt 50 C43263
SNOMED-CT 68 15771004 190484000
UMLS 73 C0011848

Summaries for Diabetes Insipidus

MedlinePlus : 43 Diabetes insipidus (DI) causes frequent urination. You become extremely thirsty, so you drink. Then you urinate. This cycle can keep you from sleeping or even make you wet the bed. Your body produces lots of urine that is almost all water. DI is different from diabetes mellitus (DM), which involves insulin problems and high blood sugar. The symptoms can be similar. However, DI is related to how your kidneys handle fluids. It's much less common than DM. Urine and blood tests can show which one you have. Usually, DI is caused by a problem with your pituitary gland or your kidneys. Treatment depends on the cause of the problem. Medicines can often help. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Diabetes Insipidus is related to diabetes insipidus, nephrogenic, x-linked and wolfram syndrome 1. An important gene associated with Diabetes Insipidus is AVP (Arginine Vasopressin), and among its related pathways/superpathways are Neuroscience and Glucose / Energy Metabolism. The drugs Furosemide and Hydrocortisone have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and pituitary, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 76 Diabetes insipidus (DI) is a condition characterized by large amounts of dilute urine and increased... more...

Related Diseases for Diabetes Insipidus

Diseases in the Diabetes Insipidus family:

Hereditary Central Diabetes Insipidus Acquired Central Diabetes Insipidus

Diseases related to Diabetes Insipidus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 370)
# Related Disease Score Top Affiliating Genes
1 diabetes insipidus, nephrogenic, x-linked 35.2 AQP2 AVPR2
2 wolfram syndrome 1 34.0 AVP WFS1
3 wolfram syndrome 33.7 AVP CISD2 WFS1
4 diabetes insipidus, nephrogenic, autosomal 33.4 AQP2 ARHGAP4 AVP AVPR2 CLCNKA SLC12A1
5 wolfram syndrome 2 32.6 CISD2 WFS1
6 diabetes insipidus, neurohypophyseal 32.1 AQP2 AVP AVPR2 POMC PRL WFS1
7 nephrogenic syndrome of inappropriate antidiuresis 30.7 AVP AVPR2
8 burns 30.1 CRH INS
9 syndrome of inappropriate antidiuretic hormone 29.9 AQP2 AVP AVPR2 POMC
10 hypoaldosteronism 29.7 POMC REN
11 hypoadrenalism 29.7 CRH POMC
12 bartter disease 29.5 CLCNKA REN SLC12A1
13 empty sella syndrome 29.4 POMC PRL
14 pituitary infarct 29.1 POMC PRL
15 adenohypophysitis 29.0 POMC PRL
16 conn's syndrome 29.0 CRH POMC REN
17 pituitary apoplexy 28.9 INS POMC PRL
18 amenorrhea 28.7 CRH POMC PRL
19 hypokalemia 28.6 AQP2 POMC REN SLC12A1
20 hypopituitarism 28.4 CRH INS POMC PRL
21 acromegaly 28.4 INS POMC PRL
22 anorexia nervosa 28.1 CRH POMC PRL
23 chromophobe adenoma 28.0 AVP INS POMC PRL
24 sheehan syndrome 27.6 CRH INS POMC PRL
25 diabetes insipidus, nephrogenic, with mental retardation and intracerebral calcification 12.3
26 hereditary central diabetes insipidus 12.3
27 acquired central diabetes insipidus 12.3
28 gestational diabetes insipidus 12.3
29 dipsogenic diabetes insipidus 12.2
30 hypopituitarism, congenital, with central diabetes insipidus 12.0
31 x-linked intellectual disability-limb spasticity-retinal dystrophy-diabetes insipidus syndrome 12.0
32 langerhans cell histiocytosis 11.4
33 wolfram syndrome, mitochondrial form 11.0
34 hyperostosis frontalis interna 11.0
35 polyhydramnios, megalencephaly, and symptomatic epilepsy 11.0
36 wolfram-like syndrome, autosomal dominant 11.0
37 culler-jones syndrome 11.0
38 hashimoto-pritzker syndrome 11.0
39 bronchus cancer 10.8 AVP AVPR2
40 seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance 10.7 AQP2 AVP
41 peripheral vertigo 10.6 AQP2 AVP
42 benign essential hypertension 10.6 AVP REN
43 secondary adrenal insufficiency 10.5 AVP INS
44 vestibular disease 10.5 AQP2 AVP
45 central nervous system germinoma 10.4 AVP POMC
46 tuberculous epididymitis 10.4 AVP POMC
47 central nervous system germ cell tumor 10.4 AVP POMC
48 tuberculous empyema 10.4 AVPR2 POMC
49 histiocytosis 10.4
50 diabetes mellitus 10.3

Comorbidity relations with Diabetes Insipidus via Phenotypic Disease Network (PDN):


Acute Cystitis Diabetes Insipidus, Nephrogenic, Autosomal
Hypothyroidism Pituitary Hormone Deficiency, Combined, 2

Graphical network of the top 20 diseases related to Diabetes Insipidus:



Diseases related to Diabetes Insipidus

Symptoms & Phenotypes for Diabetes Insipidus

MGI Mouse Phenotypes related to Diabetes Insipidus:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.11 AQP2 POMC AVP PRL AVPR2 REN
2 homeostasis/metabolism MP:0005376 10 INS AQP2 POMC AVP PRL AVPR2
3 growth/size/body region MP:0005378 9.97 INS AQP2 POMC AVPR2 REN CISD2
4 integument MP:0010771 9.81 INS AQP2 POMC PRL AVPR2 CISD2
5 mortality/aging MP:0010768 9.61 INS AQP2 AVP POMC AVPR2 REN
6 renal/urinary system MP:0005367 9.28 POMC AVP AVPR2 REN CISD2 SLC12A1

Drugs & Therapeutics for Diabetes Insipidus

Drugs for Diabetes Insipidus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 358)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Furosemide Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 54-31-9 3440
2
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 50-23-7 5754
3
Sevoflurane Approved, Vet_approved Phase 4,Phase 1,Not Applicable 28523-86-6 5206
4
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-41-2 439260
5
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 1,Not Applicable 2078-54-8 4943
6
Conivaptan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 210101-16-9 151171
7
Tolvaptan Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 150683-30-0 216237
8
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-43-4 5816
9
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 329-65-7 838
10
Ephedrine Approved Phase 4,Phase 2,Not Applicable 299-42-3 9294
11
Pseudoephedrine Approved Phase 4,Phase 2,Not Applicable 90-82-4 7028
12
Phenylephrine Approved Phase 4,Phase 2,Not Applicable 59-42-7 6041
13
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
14
Oxymetazoline Approved, Investigational Phase 4,Phase 2,Not Applicable 1491-59-4 4636
15
Benzocaine Approved, Investigational Phase 4,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
16
Misoprostol Approved Phase 4 59122-46-2 5282381
17
Chlorothiazide Approved, Vet_approved Phase 4 58-94-6 2720
18
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
19
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
20
Metolazone Approved Phase 4,Phase 1 17560-51-9 4170
21 tannic acid Approved, Nutraceutical Phase 4,Phase 2,Not Applicable
22
Butyric Acid Experimental, Investigational Phase 4,Phase 3 107-92-6 264
23
Synephrine Experimental Phase 4 1994-07-5, 94-07-5 7172
24 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 diuretics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
26 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
28 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Adrenergic Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Adrenergic beta-Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Mydriatics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Natriuretic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Coagulants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Sodium Potassium Chloride Symporter Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
36 Cortisol succinate Phase 4,Phase 2,Phase 3
37 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Hemostatics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Anesthetics Phase 4,Phase 1,Not Applicable
41 Deamino Arginine Vasopressin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Anesthetics, General Phase 4,Phase 1,Not Applicable
44 Anesthetics, Inhalation Phase 4,Phase 1,Not Applicable
45 Anesthetics, Intravenous Phase 4,Phase 1,Not Applicable
46 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Oxytocics Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 437)
# Name Status NCT ID Phase Drugs
1 Pharmacokinetics and Pharmacodynamics of Desmopressin Oral Lyophilisate Formulation in the Paediatric Population Unknown status NCT02584231 Phase 4 desmopressin
2 Desmopressin for Improving Nocturnal Enuresis in Patients After Radical Cystectomy With Bladder Reconstruction Unknown status NCT01582542 Phase 4 Desmopressin
3 Desmopressin Melt Therapy in Nocturnal Polyuria Patients: Pharmacodynamic Study Unknown status NCT01439997 Phase 4 Desmopressin
4 Desmopressin for Bleeding Related to Low Body Temperature Unknown status NCT00902057 Phase 4 desmopressin;desmopressin;desmopressin;placebo
5 Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites Unknown status NCT01716611 Phase 4 Tolvaptan;placebo
6 Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites Unknown status NCT01552590 Phase 4 Tolvaptan;Placebo
7 Pilot Study of Using Copeptin to Predict Response to Tolvaptan Completed NCT01346072 Phase 4 tolvaptan
8 1-deamino 8-d-arginine Vasopressin (DDAVP) in Percutaneous Ultrasound-guided Renal Biopsy Completed NCT00748072 Phase 4 DDAVP;saline solution
9 Vasopressin and Epinephrine Versus Epinephrine Alone in Cardiac Arrest Completed NCT00127907 Phase 4 epinephrine (1 mg/1 mL);arginine-vasopressin (40 UI/2 mL)
10 Desmopressin in Cardiac Surgery Completed NCT00337766 Phase 4 Desmopressin (DDAVP);Placebo
11 Desmopressin in the Treatment of Mixed Nocturia With Nocturnal Polyuria and Low Nocturnal Bladder Capacity Completed NCT00902655 Phase 4 Desmopressin
12 Study of the Use of Misoprostol to Decrease Bleeding During a Myomectomy Completed NCT01700478 Phase 4 Misoprostol + vasopressin;Vasopressin
13 Desmopressin Melt: Impact on Sleep and Daytime Functioning Completed NCT01645475 Phase 4 Desmopressin lyophilisate (Melt)
14 Effects of Tolvaptan in Healthy Adults Completed NCT01973140 Phase 4 Tolvaptan;Hypertonic saline infusion
15 Effects on Exercise Hemodynamics of Vasopressin Blockade by Conivaptan Infusion in Heart Failure Patients Completed NCT01752543 Phase 4 Conivaptan;Placebo (Dextrose)
16 A New Check-list Method for Nocturnal Enuresis Completed NCT03510975 Phase 4 desmopressin melt form 120 μg
17 Effects of Desmopressin on Blood Loss and the Quality of the Surgical Field During Endoscopic Sinus Surgery Completed NCT02125188 Phase 4 Desmopressin;saline
18 Severe Aortic Stenosis and Acquired Von Willebrand´s Disease: The Impact of Desmopressin in Valve-Replacement Surgery Completed NCT01994330 Phase 4 desmopressin
19 Desmopressin Melt Therapy in Patients With Nocturnal Polyuria: a Pharmacokinetic/Dynamic Study Completed NCT01435083 Phase 4 Desmopressin
20 Influence of Food-intake on Desmopressin Oral Tablets and MELT-formulation Completed NCT01036841 Phase 4 desmopressin tablet;desmopressin MELT formulation
21 A Study of Oral Desmopressin in Previously Untreated Children Aged 5 to 15 Years With Primary Nocturnal Enuresis Completed NCT00245479 Phase 4 Primary nocturnal enuresis
22 A 6-week Open Label Cross-over Study With 2 Different Daily Doses of Minirin® Oral Lyophilisate in Children and Adolescents With Primary Nocturnal Enuresis (PNE) Completed NCT00209261 Phase 4 MINIRIN Oral Lyophilisate;Minirin tablet
23 Vasopressin Administration During Laparoscopic Myomectomy: a Randomized Controlled Trial Completed NCT01393704 Phase 4 Vasopressin
24 Comparison of the Effects of Cervical Vasopressin Versus no Premedication on Blood Loss During Vaginal Hysterectomy: A Randomized, Placebo Controlled Trial Completed NCT00799292 Phase 4 Vasopressin
25 Effects of Vasopressors on Immune Response Completed NCT02675868 Phase 4 Norepinephrine;Phenylephrine;Vasopressins;Placebo
26 Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients Completed NCT01439009 Phase 4 Tolvaptan;Placebo of tolvaptan
27 Tolvaptan for Ascites in Cirrhotic Patients Completed NCT01292304 Phase 4 Tolvaptan
28 Tolvaptan in Hyponatremic Cancer Patients Completed NCT01199198 Phase 4 Tolvaptan;Placebo
29 A Study of Multiple Dosing Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia Completed NCT00435591 Phase 4 Conivaptan;placebo
30 Tolvaptan/Ultrafiltration in the Treatment of Acute Heart Failure Completed NCT01863511 Phase 4 loop diuretic;tolvaptan
31 The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement Completed NCT02644616 Phase 4 tolvaptan+torasemide;placebo+torasemide
32 Metabolism of Isotonic Versus Hypotonic Maintenance Solutions in Fasting Healthy Adults Completed NCT02822898 Phase 4 NaCl 0.9% in Glucose 5% with 40mEq Potassium;Glucion 5%
33 Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders Recruiting NCT02476409 Phase 4 tolvaptan
34 The Effect of MIDazolam PREmedication on COPeptine Concentration in Blood Recruiting NCT03474939 Phase 4 Midazolam Oral Tablet
35 The Effect of Selecting Treatment With Desmopressin or Alarm to Children With Enuresis Based on Home Recordings. Recruiting NCT03389412 Phase 4 Desmopressin
36 The Effect of Propofol or Sevoflurane on Renal Function Recruiting NCT03336801 Phase 4 Propofol;Sevoflurane
37 Exercise Versus DDAVP in Patients With Mild Hemophilia A Recruiting NCT03379974 Phase 4 DDAVP Inhalant Product
38 DDAVP vs. Exercise in Patients With Mild Hemophilia A Recruiting NCT03136003 Phase 4 DDAVP
39 Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery Recruiting NCT02549768 Phase 4 Dexmedetomidine;Sodium Chloride 0.9%
40 Regional Tolvaptan Registry Recruiting NCT02666651 Phase 4 Tolvaptan
41 Tolvaptan for Advanced or Refractory Heart Failure Recruiting NCT02959411 Phase 4 Tolvaptan;Standard of care diuretic therapy
42 Aquaresis Utility for Hyponatremic Acute Heart Failure Study Recruiting NCT02183792 Phase 4 Tolvaptan;Furosemide
43 Effect of Vasopressin, Steroid, and Epinephrine Treatment in Patients With Out-of-hospital Cardiac Arrest Recruiting NCT03317197 Phase 4 Control Group;Experimental Group 1;Experimental Group 2;Experimental Group 3
44 Vasoactive Drugs in Intensive Care Unit Recruiting NCT02118467 Phase 4 Norepinephrine;Epinephrine;Phenylephrine;Vasopressin
45 Effects of Prophylactic Desmopressin on Blood Coagulation Parameters in Heart Valve Surgery Active, not recruiting NCT03343418 Phase 4 Desmopressin;Placebo
46 Comparison of Oral or Intravenous Thiazides vs Tolvaptan in Diuretic Resistant Decompensated Heart Failure Enrolling by invitation NCT02606253 Phase 4 tolvaptan;Chlorothiazide;Metolazone
47 Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia Terminated NCT01890694 Phase 4 Tolvaptan;Placebo
48 Desmopressin as Treatment for Postoperative Bleeding After Cardiac Surgery Terminated NCT00885924 Phase 4 Desmopressin;Placebo
49 Effect of Desmopressin on the Nocturnal Micturition Frequency in Patients With Parkinson Disease Terminated NCT00806468 Phase 4 Desmotabs
50 Outcome and Treatment Quality Study of Tolvaptan to Treat Hyponatremia in Patients With Heart Failure Terminated NCT02352285 Phase 4 Tolvaptan;Placebo

Search NIH Clinical Center for Diabetes Insipidus

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: diabetes insipidus

Genetic Tests for Diabetes Insipidus

Genetic tests related to Diabetes Insipidus:

# Genetic test Affiliating Genes
1 Diabetes Insipidus 29

Anatomical Context for Diabetes Insipidus

MalaCards organs/tissues related to Diabetes Insipidus:

41
Heart, Kidney, Pituitary, Brain, Liver, Testes, Lung

Publications for Diabetes Insipidus

Articles related to Diabetes Insipidus:

(show top 50) (show all 1345)
# Title Authors Year
1
Hemorrhagic fever with renal syndrome accompanied by panhypopituitarism and central diabetes insipidus: a case report. ( 29508304 )
2018
2
Oxcarbazepine Therapy for Complete Central Diabetes Insipidus. ( 29594147 )
2018
3
Delayed Occurrence of Diabetes Insipidus After Transsphenoidal Surgery with Radiologic Evaluation of the Pituitary Stalk on Magnetic Resonance Imaging. ( 29229338 )
2018
4
Contiguous 22.1-kb deletion embracing AVPR2 and ARHGAP4 genes at novel breakpoints leads to nephrogenic diabetes insipidus in a Chinese pedigree. ( 29394883 )
2018
5
SOCIETY FOR ENDOCRINOLOGY CLINICAL GUIDANCE: Inpatient management of cranial diabetes insipidus. ( 29930026 )
2018
6
Novel and recurrent variants in AVPR2 in 19 families with X-linked congenital nephrogenic diabetes insipidus. ( 29594432 )
2018
7
AKAPs-PKA disruptors increase AQP2 activity independently of vasopressin in a model of nephrogenic diabetes insipidus. ( 29650969 )
2018
8
Postoperative Diabetes Insipidus and Hyponatremia in Children after Transsphenoidal Surgery for Adrenocorticotropin Hormone and Growth Hormone Secreting Adenomas. ( 29395172 )
2018
9
Rapid differential diagnosis of diabetes insipidus in a 7-month-old infant: The copeptin approach. ( 29241593 )
2018
10
For Debate: Personalized Health Care: As Exemplified by Home Sodium Measurements in a Child with Central Diabetes Insipidus and Impaired Thirst Perception. ( 29806747 )
2018
11
One too many diabetes: the combination of hyperglycaemic hyperosmolar state and central diabetes insipidus. ( 29675260 )
2018
12
Bartter Syndrome Type 1 Presenting as Nephrogenic Diabetes Insipidus. ( 29527380 )
2018
13
From Mechanical to Chemical: A Case of Diabetes Insipidus Induced by Concussive Brain Injury. ( 29596786 )
2018
14
Diabetes Insipidus following Endoscopic Transsphenoidal Surgery for Pituitary Adenoma. ( 29868315 )
2018
15
Systemic lupus erythematosus with SjAPgren's syndrome and renal tubular acidosis presenting as nephrogenic diabetes insipidus. ( 29657217 )
2018
16
Nephrogenic diabetes insipidus in initial stage of acute lymphoblastic leukemia and relapse after haploidentical hematopoietic stem-cell transplantation: A case report. ( 29901649 )
2018
17
Functional characterization of AVPR2 mutants found in Turkish patients with nephrogenic diabetes insipidus. ( 29117938 )
2018
18
Relation between change in treatment for central diabetes insipidus and body weight loss. ( 29424204 )
2018
19
A rat model for pituitary stalk electric lesion-induced central diabetes insipidus: application of 3D printing and further outcome assessments. ( 29681579 )
2018
20
Chemical chaperone 4-phenylbutylate reduces mutant protein accumulation in the endoplasmic reticulum of arginine vasopressin neurons in a mouse model for familial neurohypophysial diabetes insipidus. ( 29886132 )
2018
21
Diabetes insipidus is an unfavorable prognostic factor for response to glucocorticoids in patients with autoimmune hypophysitis. ( 29141992 )
2018
22
Tamoxifen attenuates development of lithium-induced nephrogenic diabetes insipidus in rats. ( 29357422 )
2018
23
Anti-PD-L1 Treatment Induced Central Diabetes Insipidus. ( 29220526 )
2018
24
Resolution of Diabetes Insipidus After Pyeloplasty: A Case Report and Review of the Literature. ( 29499256 )
2018
25
Severe localised granulomatosis with polyangiitis (Wegener's granulomatosis) manifesting with extensive cranial nerve palsies and cranial diabetes insipidus: a case report and literature review. ( 29716529 )
2018
26
Brain Death in Children: Incidence, Donation Rates, and the Occurrence of Central Diabetes Insipidus. ( 29967895 )
2018
27
A novel mechanism of autophagy-associated cell death of vasopressin neurons in familial neurohypophysial diabetes insipidus. ( 29961215 )
2018
28
'If there were water we should stop and drink': neurofibromatosis presenting with diabetes insipidus. ( 29440241 )
2018
29
Treatment of congenital nephrogenic diabetes insipidus in pregnancy. ( 29512817 )
2018
30
Cardiovascular autonomic dysfunction in patients with idiopathic diabetes insipidus. ( 29081004 )
2018
31
Transient diabetes insipidus in a post-partum woman with pre-eclampsia associated with residual placental vasopressinase activity. ( 29850023 )
2018
32
The clinical course and pathophysiological investigation of adolescent gestational diabetes insipidus: a case report. ( 29378555 )
2018
33
Overlap of Post-obstructive Diuresis and Unmasked Diabetes Insipidus in a Case of IgG4-related Retroperitoneal Fibrosis and Tuberoinfundibular Hypophysitis: A Case Report and Review of the Literature. ( 28049999 )
2017
34
Opioid-induced hyponatremia in a patient with central diabetes insipidus: independence from ADH. ( 28593907 )
2017
35
Treatment regimens by pediatric nephrologists in children with congenital nephrogenic diabetes insipidus: A MWPNC studya8c. ( 29162216 )
2017
36
A case of gestational central diabetes insipidus with oligohydramnios. ( 28764595 )
2017
37
Diabetes insipidus after discontinuation of vasopressin infusion for septic shock. ( 28895166 )
2017
38
A Case of Osteomyelitis of the toe caused by Coccidioidomycosis in a 17 year-old with Diabetes Insipidus. ( 28560172 )
2017
39
Xanthomatous Hypophysitis Presenting with Diabetes Insipidus Completely Cured Through Transsphenoidal Surgery: Case Report and Literature Review. ( 28583458 )
2017
40
Two Cases of Central Diabetes Insipidus in Refractory Antineutrophil Cytoplasmic Antibody-associated Vasculitis. ( 28943556 )
2017
41
Delirium after thiazide diuretic suspension can unmask diabetes insipidus. ( 29265751 )
2017
42
Diabetes Insipidus ( 29262153 )
2017
43
Diabetes insipidus and the use of desmopressin in hospitalised children. ( 28073809 )
2017
44
Mice deficient for ERAD machinery component Sel1L develop central diabetes insipidus. ( 28920918 )
2017
45
The soluble (Pro) renin receptor does not influence lithium-induced diabetes insipidus but does provoke beiging of white adipose tissue in mice. ( 29138356 )
2017
46
Tuberculoma of the pituitary gland presenting as diabetes insipidus. ( 28681785 )
2017
47
Diabetes insipidus and hypopituitarism in HIV: an unexpected cause. ( 28620498 )
2017
48
Novel<i>de novo AVPR2</i>Variant in a Patient with Congenital Nephrogenic Diabetes Insipidus. ( 29177155 )
2017
49
Hereditary Nephrogenic Diabetes Insipidus: Pathophysiology and Possible Treatment. An Update. ( 29125546 )
2017
50
Pulmonary langerhans cell histiocytosis case with diabetes insipidus and tuberculosis. ( 28406136 )
2017

Variations for Diabetes Insipidus

ClinVar genetic disease variations for Diabetes Insipidus:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MATN4 NM_030590.3(MATN4): c.515G> C (p.Gly172Ala) single nucleotide variant Likely pathogenic rs730882210 GRCh38 Chromosome 20, 45304356: 45304356
2 MATN4 NM_030590.3(MATN4): c.515G> C (p.Gly172Ala) single nucleotide variant Likely pathogenic rs730882210 GRCh37 Chromosome 20, 43932996: 43932996

Expression for Diabetes Insipidus

Search GEO for disease gene expression data for Diabetes Insipidus.

Pathways for Diabetes Insipidus

GO Terms for Diabetes Insipidus

Cellular components related to Diabetes Insipidus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.43 AVP CRH INS POMC PRL REN
2 endosome lumen GO:0031904 8.62 INS PRL

Biological processes related to Diabetes Insipidus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.76 AVP INS POMC PRL
2 positive regulation of gene expression GO:0010628 9.67 AVP AVPR2 CRH INS
3 positive regulation of cell proliferation GO:0008284 9.55 AVP AVPR2 CRH INS PRL
4 glucose homeostasis GO:0042593 9.5 INS POMC WFS1
5 positive regulation of vasoconstriction GO:0045907 9.48 AVP AVPR2
6 response to immobilization stress GO:0035902 9.43 CRH REN
7 water transport GO:0006833 9.4 AQP2 AVP
8 positive regulation of systemic arterial blood pressure GO:0003084 9.26 AVP AVPR2
9 excretion GO:0007588 9.13 AQP2 AVPR2 CLCNKA
10 renal water homeostasis GO:0003091 8.92 AQP2 AVP AVPR2 WFS1

Molecular functions related to Diabetes Insipidus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.56 AVP CRH POMC REN
2 insulin-like growth factor receptor binding GO:0005159 9.16 INS REN
3 neuropeptide hormone activity GO:0005184 9.13 AVP CRH POMC
4 hormone activity GO:0005179 9.02 AVP CRH INS POMC PRL

Sources for Diabetes Insipidus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....